CICC Qiyuan National Emerging Industry Private Equity Venture Capital Investment Fund
中金启元国家新兴产业创业投资引导基金
CICC Qiyuan National Emerging Industry Private Equity Venture Capital Investment Fund is a fund under CICC Capital, the asset management arm of CICC (China International Capital Corporation). In the available corpus, it appears as a co-lead investor in CytoNiche's nearly RMB 300 million Series B round in March 2022, alongside Gaorong Capital and CICC Qide Fund . elsewhere's corpus does not contain further details on its vintage, scale, or specific investment mandate beyond this single transaction.
AI-generated — may contain errors, please verify.
Coverage
Harry Wang, Founder and CEO of Linear Capital, spoke at a CICC Capital Qiyuan Lecture event, sharing frontier technology investment strategies from a global perspective.
On March 25, the 49th Qiyuan Lecture Hall, organized by CICC Qiyuan National Emerging Industry Venture Capital Guidance Fund, was successfully held in Wuhan. The event featured Harry Wang, CEO and founder of Linear Capital, delivering a keynote speech titled *Frontier Tech Investment Strategy from a Global Perspective x China Dividend 2.0*. The event was supported by the Wuhan Donghu New Technology Development Zone Management Committee, and co-hosted by the Hubei Provincial Government Investment Guidance Fund, the Wuhan Donghu New Technology Development Zone Financial Work Bureau, and Wu
Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
Viva Biotech Completes Nearly RMB 300 Million Series B Funding Round to Accelerate Industrialization of 3D Cell "Smart Manufacturing"
Gaorong Ventures co-led the round.
